Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer

Future Oncol. 2021 Mar;17(8):877-892. doi: 10.2217/fon-2020-0655. Epub 2020 Nov 30.


Immune checkpoint inhibitors have demonstrated significant clinical activity across various tumor subtypes; however, their utility in gynecologic malignancies has thus far proven modest. Since the identification of a molecular subclassification system for endometrial cancer (EC), research in immune checkpoint inhibitor therapies has been focusing on certain subgroups predictive for response, particularly microsatellite instability hypermutated/DNA mismatch repair-deficient subtype. Dostarlimab, a PD-1 inhibitor, has demonstrated preliminary evidence of clinical activity and acceptable safety profile in patients with across recurrent EC, particularly microsatellite instability-hypermutated/DNA mismatch repair-deficient EC. This review outlines existing data for the efficacy and safety of dostarlimab in recurrent or advanced-stage EC.

Keywords: PD-1 inhibitor; TSR-042; dostarlimab; endometrial carcinoma; gynecologic/endometrial; immune checkpoint inhibitor; immunotherapy.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal, Humanized / pharmacology
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Clinical Trials as Topic
  • DNA Mismatch Repair
  • Disease-Free Survival
  • Disulfides / pharmacology
  • Disulfides / therapeutic use
  • Endometrial Neoplasms / diagnosis
  • Endometrial Neoplasms / drug therapy*
  • Endometrial Neoplasms / genetics
  • Endometrial Neoplasms / mortality
  • Female
  • Humans
  • Immune Checkpoint Inhibitors / pharmacology
  • Immune Checkpoint Inhibitors / therapeutic use*
  • Microsatellite Instability
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / epidemiology
  • Neoplasm Recurrence, Local / genetics
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*


  • Antibodies, Monoclonal, Humanized
  • Disulfides
  • Immune Checkpoint Inhibitors
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • dostarlimab